Plain-English translation of NCT05020236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called for people whose multiple myeloma has returned or stopped responding to previous treatments. The study compares this medication alone, this medication combined with another antibody drug, and a standard combination therapy to see which works best and is safest for patients.
Multiple myeloma often becomes resistant to standard treatments over time, leaving patients with few good options. This trial is testing whether this new treatment approach can help people whose cancer has stopped responding to earlier therapies.
You likely qualify if…
You likely don't qualify if…
The study has multiple stages. First, researchers will test different doses of the medication to find the safest dose. Then, participants will be randomly assigned to receive one of three treatments: the new medication alone, the new medication combined with another antibody drug, or a standard combination of three existing drugs. You will continue receiving your assigned treatment until your cancer progresses, side effects become too difficult, or you decide to stop. The study involves regular clinic visits for blood tests, imaging scans, and monitoring of how you're doing.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States